Quick Takeaways:
- Gallant partnered with MWI Animal Health (part of Cencora) to establish the first ultra-low temperature (-80°C) cold chain in veterinary medicine, supporting next-gen stem cell therapies for pets.
- The infrastructure will enable delivery of Gallant’s lead candidate sonruvetcel, a potential first-in-class allogeneic stem cell therapy for refractory feline chronic gingivostomatitis (rFCGS), as the company advances toward potential FDA-CVM conditional approval.
- With overnight nationwide distribution from Kansas, the partnership ensures clinics can access ready-to-use, off-the-shelf regenerative therapies, while setting the foundation for scaling future cell-based treatments across veterinary care.
Why It Matters?
The partnership gives Gallant industrial‑grade cold-chain logistics, solving a key bottleneck for scaling allogeneic cell therapies beyond a few specialty centers.
For MWI/Cencora, establishing -80°C capability positions the network as the default distribution backbone for future veterinary regenerative products, strengthening its role with advanced-care clinics.
Source: PRnewswire
